Cephalalgia

1. DE BOER I, Kopruszinski CM
   2025 Highlights in sex and gender differences in migraine.
   Cephalalgia. 2026;46:3331024261417385.
   

   >> Share

   
   
2. IANNONE LF, Piella EM, Montisano DA, Fasano C, et al
   Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study).
   Cephalalgia. 2026;46:3331024251414659.
   

   >> Share

   
   

   
   Headache

3. 
   Correction to "Migraine and air pollution: A systematic review".
   Headache. 2026 Feb 12. doi: 10.1111/head.70053.
   

   >> Share

   
   
4. GRAVES KS, To J, Paige H, Kennedy AG, et al
   Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.
   Headache. 2026 Feb 12. doi: 10.1111/head.70057.
   

   >> Share

   
   
5. CHARLESTON L 4TH, Armand CE, Monteith TS, O'Brien HL, et al
   Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials.
   Headache. 2026 Feb 6. doi: 10.1111/head.70034.
   

   >> Share

   
   
6. TOURLAS K, Ilangovan S, White C, Irwin SL, et al
   Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents.
   Headache. 2026 Feb 6. doi: 10.1111/head.70033.
   

   >> Share

   
   

   
   PLoS One

7. HUANG Y, Liu D, Zhang H, Xu X, et al
   Trends and age-period-cohort analysis of migraine incidence in China from 1990 to 2021.
   PLoS One. 2026;21:e0338930.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share